Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swedish Orphan Biovitrum (Sobi) has inked a research collaboration and option agreement with Affibody to discover and develop new treatments for inflammatory diseases where Interleukin-1 (IL-1) is implicated.
Subscribe to our email newsletter
The research, which will be based on Affibody’s proprietary technology platforms, Affibody molecules and Albumod, will include nearly five different targets within the IL-1 field.
The research agreement covers a two-year period initially during which Sobi has a feasibility to enter into a licensing agreement with worldwide rights to any or all of the development projects.
As part of the agreement, Sobi will make initial payments, in addition to future milestones and royalty after the two year period.
Affibody will take care of the discovery phase and Sobi for clinical development.
Sobi CEO Geoffrey McDonough said, "We believe the Affibody platform offers potentially unique therapeutic advantages, and the efficient translation from discovery to biologics development offered by our close association fits our innovation model very well.”
Affibody CEO David Bejker said, "IL-1 biology offers a number of opportunities to address unmet medical needs and we believe that Sobi is in a good position to capitalize on this segment based on their capabilities and existing presence in the field."